Tag: Immunotherapy
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver Cancer
Age and immune checkpoint inhibitor washout time inversely linked to allograft rejection; survival no different with, without allograft rejection
Gene Expression Signature Predicts Immune-Related Adverse Events in Melanoma Patients
Gene expression signature predicts irAEs in melanoma patients treated with ipilimumab/nivolumab
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
Reduction seen in hypogammaglobulinemia, infections or severe infections, and associated antimicrobial use
Alternative Pembrolizumab Administration Yields Environmental Advantages
Weight-based, extended interval dosing and pharmacy-level stewardship strategies would result in fewer administration events
ASCO: Ivonescimab Improves Progression-Free Survival in EGFR+ Lung Cancer
PFS benefit seen in most subgroups, including those whose disease progressed while receiving third-generation EGFR-TKIs
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
113 of 115 enrolled patients underwent timely surgery; two had surgery delayed by more than two weeks
Recommendations Developed to Prepare Patients for Oral Immunotherapy
76 statements specific to OIT preparatory procedures were included, as well as 71 on the consent information form
Guideline Issued for Management of Inhalant Allergies With Immunotherapy
Authors strongly recommend that clinician performing allergy skin testing or allergen immunotherapy be able to diagnose, manage anaphylaxis
Pembrolizumab Improves Event-Free Survival in Early NSCLC
For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery
Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy
Projected five-year incidence of 15.2 and 2.3 percent for solid and hematologic malignancies after CAR T-cell immunotherapy
